Plant derived anti-cancerous secondary metabolites as multipronged inhibitor of COX, Topo, and aromatase: molecular modeling and dynamics simulation analyses

References

• Accelrys Software Inc. (2013). Discovery studio modeling environment (Release 3.1). San Diego, CA: Author.
   Google Scholar
• Aggarwal, B. B., Shishodia, S., Sandur, S. K., Pandey, M. K., & Sethi, G. (2006). Inflammation and cancer: How hot is the link? Biochemical Pharmacology, 72, 1605–1621.10.1016/j.bcp.2006.06.029
   PubMed Web of Science ®Google Scholar
• Awasthi, M., Singh, S., Pandey, V. P., & Dwivedi, U. N. (2015). Molecular docking and 3D-QSAR-based virtual screening of flavonoids as potential aromatase inhibitors against estrogen-dependent breast cancer. Journal of Biomolecular Structure and Dynamics, 33, 804–819.10.1080/07391102.2014.912152
   PubMed Web of Science ®Google Scholar
• Balkwill, F., & Mantovani, A. (2001). Inflammation and cancer: Back to Virchow? The Lancet, 357, 539–545.10.1016/S0140-6736(00)04046-0
   PubMed Web of Science ®Google Scholar
• Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., … Bourne, P.E. (2000). The protein data bank. Nucleic Acids Research, 28, 235–242.10.1093/nar/28.1.235
   PubMed Web of Science ®Google Scholar
• Brower, V. (2015). Aromatase inhibitors may reduce endometrial cancer risk. The Lancet Oncology, 16, e164.10.1016/S1470-2045(15)70119-1
   PubMed Web of Science ®Google Scholar
• Brueggemeier, R. W., Hackett, J. C., & Diaz-Cruz, E. S. (2005). Aromatase inhibitors in the treatment of breast cancer. Endocrine Reviews, 26, 331–345.10.1210/er.2004-0015
   PubMed Web of Science ®Google Scholar
• Brueggemeier, R. W., Richards, J. A., Joomprabutra, S., Bhat, A. S., & Whetstone, J. L. (2001). Molecular pharmacology of aromatase and its regulation by endogenous and exogenous agents. The Journal of Steroid Biochemistry and Molecular Biology, 79, 75–84.10.1016/S0960-0760(01)00127-3
   PubMed Web of Science ®Google Scholar
• Cancer Facts & Figures 2015. (2015). American Cancer Society. Retrieved from http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf
   Google Scholar
• Champoux, J. J. (2001). DNA topoisomerases: Structure, function, and mechanism. Annual Review of Biochemistry, 70, 369–413.10.1146/annurev.biochem.70.1.369
   PubMed Web of Science ®Google Scholar
• Chhatriwala, H., Jafri, N., & Salgia, R. (2006). A review of topoisomerase inhibition in lung cancer. Cancer Biology and Therapy, 5, 1600–1607.10.4161/cbt.5.12.3546
   PubMed Web of Science ®Google Scholar
• Coussens, L. M., & Werb, Z. (2002). Inflammation and cancer. Nature, 420, 860–867.10.1038/nature01322
   PubMed Web of Science ®Google Scholar
• Crusz, S. M., & Balkwill, F. R. (2015). Inflammation and cancer: Advances and new agents. Nature Reviews Clinical Oncology, 12, 584–596. doi:10.1038/nrclinonc.2015.105
   PubMed Web of Science ®Google Scholar
• Daikoku, T., Tranguch, S., Trofimova, I. N., Dinulescu, D. M., Jacks, T., Nikitin, A. Y., … Dey, S. K. (2006). Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer. Cancer Research, 66, 2527–2531.10.1158/0008-5472.CAN-05-4063
   PubMed Web of Science ®Google Scholar
• Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C., & Flavell, R. A. (2013). Inflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms. Nature Reviews Cancer, 13, 759–771.10.1038/nrc3611
   PubMed Web of Science ®Google Scholar
• Gonçalves, A. S., França, T. C. C., Figueroa-Villar, J. D., & Pascutti, P. G. (2011). Molecular dynamics simulations and QM/MM studies of the reactivation by 2-PAM of tabun inhibited human acethylcolinesterase. Journal of the Brazilian Chemical Society, 22, 155–165.10.1590/S0103-50532011000100021
   Web of Science ®Google Scholar
• Grimes, K. R., Warren, G. W., Fang, F., Xu, Y., & Clair, W. H. (2006). Cyclooxygenase-2 inhibitor, nimesulide, improves radiation treatment against non-small cell lung cancer both in vitro and in vivo. Oncology Report, 16, 771–776.
   PubMed Web of Science ®Google Scholar
• Harris, R. E., Casto, B. C., & Harris, Z. M. (2014). Cyclooxygenase-2 and the inflammogenesis of breast cancer. World Journal of Clinical Oncology, 5, 677–692.10.5306/wjco.v5.i4.677
   PubMedGoogle Scholar
• Hulka, B. S., & Moorman, P. G. (2001). Breast cancer: Hormones and other risk factors. Maturitas, 38, 103–113.
   PubMed Web of Science ®Google Scholar
• Hwang, D., Byrne, J., Scollard, D., & Levine, E. (1998). Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. Journal of National Cancer Institute, 90, 455–460.10.1093/jnci/90.6.455
   PubMed Web of Science ®Google Scholar
• Järvinen, T. A., & Liu, E. T. (2003). Her-2/neu and topoisomerase IIα in breast cancer. Breast Cancer Research Treatment, 78, 299–311.10.1023/A:1023077507295
   PubMed Web of Science ®Google Scholar
• Kang, Y. J., Mbonye, U. R., DeLong, C. J., Wada, M., & Smith, W. L. (2007). Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Progress in Lipid Research, 46, 108–125.10.1016/j.plipres.2007.01.001
   PubMed Web of Science ®Google Scholar
• Kellner, U., Sehested, M., Jensen, P. B., Gieseler, F., & Rudolph, P. (2003). Culprit and victim-DNA topoisomerase II. Lancet Oncology, 3, 235–243.
   Web of Science ®Google Scholar
• Kim, E. J., Lee, Y. S., Kim, Y. J., Kim, M. J., Ha, Y. S., Jeong, P., … Kim, W. J. (2010). Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer. Urology, 75, 1516-e9–1516-e13.
   PubMed Web of Science ®Google Scholar
• Kim, H. S., Kim, T., Kim, M. K., Suh, D. H., Chung, H. H., & Song, Y. S. (2013). Cyclooxygenase-1 and -2: Molecular targets for cervical neoplasia. Journal of Cancer Prevention, 18, 123–134.10.15430/JCP.2013.18.2.123
   PubMedGoogle Scholar
• Kirschenbaum, A., Klausner, A. P., Lee, R., Unger, P., Yao, S., Liu, X. H., & Levine, A. C. (2000). Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology, 56, 671–676.10.1016/S0090-4295(00)00674-9
   PubMed Web of Science ®Google Scholar
• Kollman, P. A., Massova, I., Reyes, C., Kuhn, B., Huo, S., Chong, L., … Cheatham, T. E. (2000). Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models. Accounts of Chemical Research, 33, 889–897.10.1021/ar000033j
   PubMed Web of Science ®Google Scholar
• Koohpar, Z. K., Entezari, M., Movafagh, A., & Hashemi, M. (2015). Anticancer activity of curcumin on human breast adenocarcinoma: Role of Mcl-1 gene. Iranian Journal of Cancer Prevention, 8, e2331. doi:10.17795/ijcp2331
   PubMed Web of Science ®Google Scholar
• Kumari, R., Kumar, R., Open Source Drug Discovery Consortium, & Lynn, A. (2014). g_mmpbsa – A GROMACS tool for high-throughput MM-PBSA calculations. Journal of Chemical Information and Modeling, 54, 1951–1962.10.1021/ci500020m
   PubMed Web of Science ®Google Scholar
• Lahlou, M. (2013). The success of natural products in drug discovery. Pharmacology & Pharmacy, 4, 17–31.10.4236/pp.2013.43A003
   Google Scholar
• Liedtke, A. J., Crews, B. C., Daniel, C. M., Blobaum, A. L., Kingsley, P. J., Ghebreselasie, K., & Marnett, L. J. (2012). Cyclooxygenase-1-selective inhibitors based on the (E)-2′-des-methyl-sulindac sulfide scaffold. Journal of Medicinal Chemistry, 55, 2287–2300.10.1021/jm201528b
   PubMed Web of Science ®Google Scholar
• Liu, Y., Gao, F., Jiang, H., Niu, L., Bi, Y., Young, C. Y., … Lou, H. (2013). Induction of DNA damage and ATF3 by retigeric acid B, a novel topoisomerase II inhibitor, promotes apoptosis in prostate cancer cells. Cancer Letters, 337, 66–76.10.1016/j.canlet.2013.05.022
   PubMed Web of Science ®Google Scholar
• López-Lázaro, M., Willmore, E., Jobson, A., Gilroy, K. L., Curtis, H., Padget, K., & Austin, C. A. (2007). Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells. Journal of Natural Products, 70, 1884–1888.10.1021/np070332i
   PubMed Web of Science ®Google Scholar
• Munster, P. N., & Daud, A. I. (2011). Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma. Expert Opinion on Investigational Drugs, 20, 1565–1574.10.1517/13543784.2011.617740
   PubMed Web of Science ®Google Scholar
• Nair, H. B., Luthra, R., Kirma, N., Liu, Y. G., Flowers, L., Evans, D., & Tekmal, R. R. (2005). Induction of aromatase expression in cervical carcinomas: Effects of endogenous estrogen on cervical cancer cell proliferation. Cancer Research, 65, 1164–1173.
   PubMed Web of Science ®Google Scholar
• Pasqualini, J. R. (2004). The selective estrogen enzyme modulators in breast cancer: A review. Biochimica et Biophysica Acta, 1654, 123–143.
   PubMed Web of Science ®Google Scholar
• Perrone, M. G., Scilimati, A., Simone, L., & Vitale, P. (2010). Selective COX-1 inhibition: A therapeutic target to be reconsidered. Current Medicinal Chemistry, 17, 3769–3805.10.2174/092986710793205408
   PubMed Web of Science ®Google Scholar
• Philip, M., Rowley, D. A., & Schreiber, H. (2004). Inflammation as a tumor promoter in cancer induction. Seminars in Cancer Biology, 14, 433–439.10.1016/j.semcancer.2004.06.006
   PubMed Web of Science ®Google Scholar
• Pronk, S., Pall, S., Schulz, R., Larsson, P., Bjelkmar, P., Apostolov, R., … Lindahl, E. (2013). GROMACS 4.5: A high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics, 29, 845–854.10.1093/bioinformatics/btt055
   PubMed Web of Science ®Google Scholar
• Qurishi, Y., Hamid, A., Zargar, M. A., Singh, S. K., & Ajit, K. S. (2010). Potential role of natural molecules in health and disease: Importance of boswellic acid. Journal of Medicinal Plants Research, 4, 2778–2785.
   Google Scholar
• Rao, C. V., Janakiram, N. B., & Mohammed, A. (2012). Lipoxygenase and cyclooxygenase pathways and colorectal cancer prevention. Current Colorectal Cancer Reports, 8, 316–324.10.1007/s11888-012-0146-1
   PubMedGoogle Scholar
• Rao, S. N., Head, M. S., Kulkarni, A., & LaLonde, J. M. (2007). Validation studies of the site-directed docking program LibDock. Journal of Chemical Information and Modeling, 47, 2159–2171.10.1021/ci6004299
   PubMed Web of Science ®Google Scholar
• Rawat, D. S., & Singh, R. (2013). Plant derived secondary metabolites as anti-cancer agents. Anti-Cancer Agents in Medicinal Chemistry, 13, 1551.10.2174/187152061310131206154445
   PubMed Web of Science ®Google Scholar
• Schneider, C., & Pozzi, A. (2011). Cyclooxygenases and lipoxygenases in cancer. Cancer and Metastasis Reviews, 30, 277–294.10.1007/s10555-011-9310-3
   PubMed Web of Science ®Google Scholar
• Singh, S., Awasthi, M., Pandey, V. P., & Dwivedi, U. N. (2016). Lipoxygenase directed anti-inflammatory and anti-cancerous secondary metabolites: ADMET based screening, molecular docking and dynamics simulation. Journal of Biomolecular Structure and Dynamics. doi:10.1080/07391102.2016.1159985
   Web of Science ®Google Scholar
• Singh, S., Awasthi, M., Pandey, V. P., Pandey, B., & Dwivedi, U. N. (2015). Molecular dynamics simulated validation of anti-cancerous alkaloids as Topo IIβ inhibitors screened by QSAR, pharmacophore and molecular docking approaches. Medicinal Chemistry Research, 24, 2972–2985.10.1007/s00044-015-1351-7
   Web of Science ®Google Scholar
• Singh, S., Pandey, V. P., Naaz, H., Singh, P., & Dwivedi, U. N. (2013). Structural modeling and simulation studies of human cyclooxygenase (COX) isozymes with selected terpenes: Implications in drug designing and development. Computers in Biology and Medicine, 43, 744–750.10.1016/j.compbiomed.2013.02.019
   PubMed Web of Science ®Google Scholar
• Tavakoli, J., Miar, S., Zadehzare, M. M., & Akbari, H. (2012). Evaluation of effectiveness of herbal medication in cancer care: A review study. Iranian Journal of Cancer Prevention, 5, 144–156.
   PubMedGoogle Scholar
• Wang, C. Z., Calway, T., & Yuan, C. S. (2012). Herbal medicines as adjuvants for cancer therapeutics. The American Journal of Chinese Medicine, 40, 657–669.10.1142/S0192415X12500498
   PubMed Web of Science ®Google Scholar
• Wang, J. C. (2002). Cellular roles of DNA topoisomerases: A molecular perspective. Nature Reviews Molecular Cell Biology, 3, 430–440.10.1038/nrm831
   PubMed Web of Science ®Google Scholar